|
Indian pharma bets big on integrated quality ecosystems to boost audit readiness and operational resilience
|
|
Nandita Vijayasimha, Bengaluru
April 15 , 2026
|
|
|
The Indian pharmaceutical industry is ramping up investments in integrated quality ecosystems as companies strive to stay audit-ready and strengthen operational resilience in an increasingly stringent global regulatory environment, said Duraisamy Rajan Palani, founder and CEO of Archimedis Digital.
The global recognition of the sector has established its status as the ‘pharmacy of the world’, which serves as a vital source for global health needs. India supplies over 20 per cent of the world’s generic medicines and accounts for a significant share consumed in major markets such as the US and Europe, he added.
As the industry expands its global footprint, the expectations surrounding quality and compliance have grown significantly. A quality lapse today does not remain confined to a single facility or geography. It travels across supply chains, regulators, and healthcare systems. In an interconnected pharmaceutical ecosystem, even isolated compliance failures can influence global trust in Indian exports, said Palani.
The upcoming leadership period for this sector, which depends on its established reliability, will require organizations to enhance their quality systems for coping with both rising regulatory demands and operational challenges.
To this end, the Archimedis Digital’s State of Digital Transformation in Indian Pharma report shows that 88 per cent of pharma implemented digital technologies for quality assurance and quality control processes. A majority of companies remain in transitional stages. Approximately 55.6 per cent of companies are implementing digital quality systems in partial implementation, whereas only one-third have reached advanced stages and only 13 per cent companies have achieved complete end-to-end integration of quality management systems.
Fragmented systems, legacy infrastructure, and the complexity of integrating multiple quality functions are all impediments to achieving progress. The visibility of risks arising from restricted digital progress has surged with the demanding international regulatory requirements. Pharmaceutical regulators across major markets are placing increasing emphasis on data integrity, traceability, and audit readiness. Manual documentation, together with disconnected quality systems, makes industrial operations vulnerable to major risks in such an environment, said Palani.
At the same time, a widening gap is emerging between digital leaders and late adopters. Digital quality systems have received investment from nearly half of pharmaceutical companies, while many others plan to invest during the next one to five years. Companies postponing these investments will experience a decline in their ability to handle inspections, operational efficiency and their global market competitiveness.
The complete digitization process now serves as an essential requirement beyond standard regulatory obligations. The process now serves as a strategic asset which affects both operational reliability, speed to market and global credibility.
Artificial intelligence is gradually emerging as the next layer of digital transformation in pharmaceutical quality. Adoption is still at an early stage. Quoting the report, Palani said that about 11 per cent of companies have already implemented AI or machine learning in their QA or QC functions. However, more than half of the industry is either piloting or planning such initiatives.
Manufacturing data analysis through AI systems enables the identification of patterns that lead to better prediction of operational deviations and strengthen preventive quality control systems. The development of automated inspection technologies enables faster and more precise execution of visual quality assessments. The existing capabilities are transforming quality management processes from their traditional reactive approaches into new methods of predictive monitoring. The next decade will require an equally strong commitment to digital quality maturity, he said.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|